Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. ABIVAX
  6. News
  7. Summary
    ABVX   FR0012333284

ABIVAX

(ABVX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

PRESS RELEASE : Abivax presents first-half 2021 -3-

09/23/2021 | 12:01pm EDT

In addition, Abivax will be hosting an Industry Symposium at the UEG Week Virtual 2021 on Monday, October 4, 2021 at 1:00-2:00 pm CEST (7:00-8:00 am EST) on "ABX464, a novel anti-inflammatory drug-candidate for the treatment of ulcerative colitis". Presentations on the continued need for novel drugs in IBD and the potential of ABX464 to address them will be given by the internationally renowned key opinion leaders Prof. Bruce Sands, M.D., M.S. and Prof. William Sandborn, M.D. In addition, Didier Scherrer, Ph.D., Vice-President R&D at Abivax, will provide more details on the novel and unique mechanism of action of ABX464.

UEG Week Virtual subscribers can follow the live symposium and view the subsequently provided on-demand replay under the following link: https://virtualweek.ueg.eu/symposium/is-10 FURTHER ANNOUNCEMENTS

Jean-Marc Steens, M.D., has decided to end his career at Abivax After more than five years as Chief Medical Officer at Abivax, Jean-Marc Steens, M.D., has decided to end his career at Abivax. Abivax would like to thank him for his contribution and wishes him all the best in his future endeavors. Sophie Biguenet, M.D., has joined Abivax as Chief Medical Officer.

*****

About Abivax (www.abivax.com) Abivax, a clinical stage biotechnology company, is developing novel therapies that modulate the physiological inflammation and immunological pathways to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax is listed on Euronext compartment B (ISIN: FR0012333284 - Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe chronic inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_. Contacts

Abivax                  Investors                      Press Relations & Investors Europe 
Communications          LifeSci Advisors               MC Services AG 
Regina Jehle            Ligia Vela-Reid                Anne Hennecke 
regina.jehle@abivax.com lvela-reid@lifesciadvisors.com anne.hennecke@mc-services.eu 
+33 6 24 50 69 63       +44 7413 825310                +49 211 529 252 22 
 
Public Relations France Public Relations France        Public Relations USA 
Actifin                 DGM Conseil                    Rooney Partners LLC 
Ghislaine Gasparetto    Thomas Roborel de Climens      Jeanene Timberlake 
ggasparetto@actifin.fr  thomasdeclimens@dgm-conseil.fr jtimberlake@rooneyco.com 
+33 6 21 10 49 24       +33 6 14 50 15 84              +1 646 770 8858 

DISCLAIMER This press release contains forward-looking statements, forecasts and estimates (including patient recruitment) with respect to certain of the Company's programs. Although the Company believes that its forward-looking statements, forecasts and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors that have been deemed reasonable, such forward-looking statements, forecasts and estimates are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated in such forward-looking statements, forecasts and estimates. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its registration document (Document d'Enregistrement Universel). Special consideration should be given to the potential hurtles of clinical and pharmaceutical development including further assessment by the company and regulatory agencies and ethics committees of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC, clinical data, Furthermore, these forward-looking statements, forecasts and estimates are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law. This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe securities of the Company in any jurisdiction, in particular in France. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgement. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.

^[1] Clinical remission (per Modified Mayo Score) is defined as stool frequency subscore (SFS) <=1, rectal bleeding subscore (RBS) of 0 and endoscopic subscore <=1.

^[2] Modified Mayo Score refers to stool frequency, rectal bleeding and endoscopy sub score.

^[3] Endoscopic improvement is defined as endoscopic subscore <=1.

^[4] Clinical response (per Modified Mayo Score) is defined as a decrease from baseline in the Modified Mayo Score > =2 points and >=30% from baseline, plus a decrease in RBS >=1 or an absolute RBS <=1.

^[5] J. Tazi et al.: Specific and selective induction of miR-124 in immune cells by the quinoline ABX464: a transformative therapy for inflammatory diseases, Drug Discovery Today, Volume 26, Issue 4, April 2021, Pages 1030-1039

^[6] Intent-to-treat patient population

^[7] S. Vermeire et al.: Induction and long-term follow-up with ABX464 for moderate-to-severe ulcerative colitis: Results of phase 2a trial, Gastroenterology, March 2021

^[8] The American College of Rheumatology ACR score measures the efficacy of treatments for rheumatoid arthritis patients. The ACR20/50/70 measures a 20/50/70% improvement in the tenderness and swelling in designated joints and a 20 /50/70% improvement in at least 3 of the 5 following measures: investigator's and patient's reported global assessment of disease scales, patient's reported pain scale, CRP level, health assessment questionnaire.

^[9] Source: Informa

-----------------------------------------------------------------------------------------------------------------------

2021-09-23 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

-----------------------------------------------------------------------------------------------------------------------

1235700 2021-09-23

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1235700&application_name=news

(END) Dow Jones Newswires

September 23, 2021 12:00 ET (16:00 GMT)

All news about ABIVAX
10/21ABIVAX : Nombre d'actions composant le capital social et nombre total de droits de vote au..
DJ
10/21Certain Ordinary Shares of ABIVAX Soci?t? Anonyme are subject to a Lock-Up Agreement En..
CI
10/19ABIVAX : Prepares Third Phase Of Ulcerative Colitis Drug Trials
MT
10/18ABIVAX : ABX464 shows excellent long-term efficacy data in Abivax's phase 2b maintenance t..
PU
10/18ABIVAX : ABX464 shows excellent long-term efficacy data in Abivax's phase 2b maintenance T..
EQ
10/18PRESS RELEASE : ABIVAX: ABX464 shows excellent long-term efficacy data in Abivax's phase 2..
DJ
10/18PRESS RELEASE : ABIVAX: ABX464 shows excellent -2-
DJ
10/18Abivax rapporte d'excellents résultats -2-
DJ
10/18Abivax rapporte d'excellents résultats d'efficacité à long terme dans l'étude de mainte..
DJ
10/18Abivax rapporte d'excellents résultats -3-
DJ
More news
Financials
Sales 2021 99,4 M 115 M 115 M
Net income 2021 8,60 M 9,97 M 9,97 M
Net cash 2021 50,3 M 58,2 M 58,2 M
P/E ratio 2021 36,5x
Yield 2021 -
Capitalization 465 M 539 M 539 M
EV / Sales 2021 4,17x
EV / Sales 2022 610x
Nbr of Employees 29
Free-Float 69,9%
Chart ABIVAX
Duration : Period :
ABIVAX Technical Analysis Chart | ABVX | FR0012333284 | MarketScreener
Technical analysis trends ABIVAX
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 28,40 €
Average target price 58,63 €
Spread / Average Target 106%
EPS Revisions
Managers and Directors
Hartmut J. Ehrlich Chief Executive Officer
Didier Blondel Chief Financial Officer & Secretary
Philippe Pouletty Chairman
Didier Scherrer Vice President-Research & Development
Paul Gineste Vice President-Clinical Operations
Sector and Competitors
1st jan.Capi. (M$)
ABIVAX-17.44%539
MODERNA, INC.230.95%139 557
LONZA GROUP AG32.63%60 898
IQVIA HOLDINGS INC.42.93%48 923
SEAGEN INC.1.46%32 330
CELLTRION, INC.-38.02%26 036